1. What is SBIR?
In 2018, for the first time, the HSE has partnered with Enterprise Ireland to develop technology -enabled solutions to specifically address challenges in the area of diabetes. Our aim is to harness digital innovation to ensure that fewer Irish citizens develop avoidable complications of diabetes, and that those who do receive appropriate care at an earlier stage. The Small Business Innovative Research Programme (SBIR) is categorised under EU law as ‘pre-commercial procurement’ or PCP. Unlike the traditional procurement process, this offers our clinicians an opportunity to identify a healthcare issue and then co-create the solution with the successful firm.
2. How does it work?
Following selection of the healthcare problem to be addressed, a tender process will result in the awarding of a number of Phase 1 ‘development contracts’. These are intended to show the technical feasibility of the proposed concept. Only those projects that have completed Phase 1 successfully will be eligible for Phase 2. Phase 2 contracts are intended to develop and evaluate prototypes from the more promising technologies in Phase 1.
3. What is the healthcare problem we are trying to solve?
Following a series of workshops held with clinicians, the following specific problems have been identified:
Reducing the risk of women developing Type 2 Diabetes following Gestational Diabetes Mellitus (GDM)
Why? Gestational diabetes (GDM) is the most common medical condition encountered in pregnancy
and rates are rising. If pregnant women develop gestational diabetes (GDM), 50% will have diabetes
within 10 years.
Screening for diabetic foot disease in all patients with diabetes
Why? In Ireland, an individual with diabetes is 22 times more likely to undergo a non-traumatic
amputation than an individual without diabetes.
4. When is this happening?
The Invitation to Tender (ITT) document goes live on e-tenders in December 2018. Shortlisting and evaluation will take place in March, with contracts projected to issue to successful applicants in April 2019.
5. I have a question about the project. Who do I talk to?
General Queries: Rosaleen Quinlan, +353 1 6352204 or email@example.com or Teresa Bennett, +353 87 050 6827 or Teresa.firstname.lastname@example.org